This study focuses on Systemic Lupus Erythematosus (SLE), an autoimmune disease where the body’s immune system attacks its own tissues, with some patients also having Lupus Nephritis, which affects the kidneys. The study will test a medicine called mosunetuzumab, which is a specialized antibody given by subcutaneous injection (injection under the skin).
The purpose of this research is to evaluate how well mosunetuzumab works in helping patients achieve disease remission. The study will include two groups of patients: those who have SLE with kidney involvement (Lupus Nephritis) and those who have SLE without kidney problems. Both groups will receive treatment with mosunetuzumab, and their health will be monitored for changes in disease activity and overall well-being.
Throughout the study, doctors will track various aspects of the participants’ health, including changes in disease symptoms, kidney function, fatigue levels, and how well the medication is tolerated. They will also monitor the levels of certain proteins in the blood that indicate disease activity and check how the body processes the medication. The study will last several years to thoroughly evaluate the long-term effects of the treatment.
Italy 
